These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 15927502)

  • 1. [Role of [18F]-fluorodeoxyglucose positron emission tomography for the initial detection, staging, search for recurrences and restaging of gynaecological and breast cancers].
    Grahek D; Barranger E; Daraï E; Uzan S; Talbot JN
    Gynecol Obstet Fertil; 2005 Jun; 33(6):371-81. PubMed ID: 15927502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET imaging in gynecologic malignancies.
    Kumar R; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1155-67, ix. PubMed ID: 15488564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Utilization of PET scan in breast and gynaecologic cancers].
    Huglo D; Vinatier D
    Gynecol Obstet Fertil; 2004 Apr; 32(4):330-9. PubMed ID: 15123104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Update of 'standards, options and recommendations' for FDG-PET in breast and gynaecological cancers].
    Talbot JN; Grahek D
    Gynecol Obstet Fertil; 2006 May; 34(5):434-6. PubMed ID: 16677841
    [No Abstract]   [Full Text] [Related]  

  • 5. [2003 update of recommendations for clinical practice: standards, options and recommendations for the use of FDG-PET in the management of gynaecological and breast cancers].
    FNCLCC
    Gynecol Obstet Fertil; 2004 Apr; 32(4):352-71. PubMed ID: 15123109
    [No Abstract]   [Full Text] [Related]  

  • 6. Positron emission tomography in gynecological malignancies.
    Kumar R; Chauhan A; Jana S; Dadparvar S
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):1033-44. PubMed ID: 16831075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [(18F)-fluoro-2-deoxyglucose PET in imaging of gynecologic cancers].
    Talbot JN; Grahek D; Kerrou K; Younsi N; de Beco V; Colombet-Lamau C; Petegnief Y; Cailleux N; Montravers F
    Gynecol Obstet Fertil; 2001 Nov; 29(11):775-98. PubMed ID: 11770272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET in gynaecological cancers: recent observations.
    Lucignani G
    Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2133-9. PubMed ID: 18779962
    [No Abstract]   [Full Text] [Related]  

  • 9. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
    Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
    J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of PET Imaging in Gynecologic Radiation Oncology.
    Rao YJ; Grigsby PW
    PET Clin; 2018 Apr; 13(2):225-237. PubMed ID: 29482751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Synthesis bulletin of 2005 surveillance. Clinical practice recommendations: the use of PET-FDG in cancers of the breast, ovary and uterus].
    Bourguet P; Hitzel A; Houvenaeghel G; Vinatier D; Bosquet L; Bonichon F; Corone C; Giard-Lefèvre S; Morett JL; Touboul E; ; ; ; ; ; ; ;
    Bull Cancer; 2006 Apr; 93(4):385-90. PubMed ID: 16714228
    [No Abstract]   [Full Text] [Related]  

  • 12. Positron emission tomography scanning in gynecologic and breast cancers.
    Zimny M; Siggelkow W
    Curr Opin Obstet Gynecol; 2003 Feb; 15(1):69-75. PubMed ID: 12544505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metabolic imaging with positron-emission tomography in the advanced-stage ovarian cancers].
    Grahek D; Hassan-Sebbag N
    Bull Cancer; 2009 Dec; 96(12):1163-71. PubMed ID: 19948451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Assessment of Gynecologic Malignancies.
    Tripathy S; Parida GK; Kumar R
    PET Clin; 2018 Apr; 13(2):269-288. PubMed ID: 29482754
    [No Abstract]   [Full Text] [Related]  

  • 15. PET/CT in gynecologic malignancies.
    Brunetti J
    Radiol Clin North Am; 2013 Sep; 51(5):895-911. PubMed ID: 24010912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET Assessment of Other Gynecologic Cancers.
    Faria S; Devine C; Viswanathan C; Javadi S; Korivi BR; Bhosale PR
    PET Clin; 2018 Apr; 13(2):203-223. PubMed ID: 29482750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gynecological cancers.
    Avril N; Gourtsoyianni S; Reznek R
    Methods Mol Biol; 2011; 727():171-89. PubMed ID: 21331934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Positron emission tomography with 18F-fluorodeoxyglucose in patients with uterine sarcoma].
    Rebollo Aguirre AC; Ramos Font C; Bellón Guardia ME; Cabello García D; Gallego Peinado M; Rodríguez Fernández A; Llamas Elvira JM
    Rev Esp Med Nucl; 2007; 26(4):189-95. PubMed ID: 17662185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer.
    Landheer ML; Steffens MG; Klinkenbijl JH; Westenberg AH; Oyen WJ
    Br J Surg; 2005 Nov; 92(11):1363-7. PubMed ID: 16187254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.